Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Novartis May Pay More Than $575M For Blood Thinner

By Pharmaceutical Processing | February 12, 2009

NEW YORK (AP) — Novartis AG said Thursday it bought for the right to develop and sell elinogrel, an experimental blood thinner being developed by Portola Pharmaceuticals Inc., in a deal that could total $575 million plus royalty payments. Elinogrel is in midstage clinical testing. Portola said the drug may offer advantages compared to Plavix, the second-best selling drug in the world, by reducing the risk of bleeding and ischemia, or reductions in blood supply. The Swiss drugmaker agreed to pay Portola $75 million upfront for elinogrel, which is designed to help prevent heart attacks and strokes by blocking a receptor on blood platelets. Novartis will pay for late-stage tests of elinogrel and could pay $500 million to Portola if the drug passes through development and regulatory goals and reaches sales targets. Portola, a privately held company based in San Francisco, also will get royalties on worldwide sales if the drug is approved, and will have the option to co-market the drug to U.S. hospitals and specialty markets. Plavix is marketed by Sanofi-Aventis and Bristol-Myers Squibb Co.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE